Rapport Therapeutics, Inc. $RAPP Shares Bought by Swiss National Bank

Swiss National Bank boosted its holdings in Rapport Therapeutics, Inc. (NASDAQ:RAPP) by 77.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,900 shares of the company’s stock after acquiring an additional 13,900 shares during the period. Swiss National Bank owned 0.09% of Rapport Therapeutics worth $320,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics in the 4th quarter valued at $41,000. Wells Fargo & Company MN lifted its holdings in shares of Rapport Therapeutics by 38.9% in the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company’s stock worth $86,000 after acquiring an additional 1,352 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Rapport Therapeutics by 77.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,170 shares of the company’s stock worth $127,000 after acquiring an additional 3,137 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Rapport Therapeutics by 1,151.2% in the 4th quarter. California State Teachers Retirement System now owns 8,571 shares of the company’s stock worth $152,000 after acquiring an additional 7,886 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Rapport Therapeutics by 91,980.0% in the 1st quarter. GAMMA Investing LLC now owns 9,208 shares of the company’s stock worth $918,000 after acquiring an additional 9,198 shares during the last quarter.

Rapport Therapeutics Trading Down 6.5%

RAPP stock opened at $14.97 on Thursday. Rapport Therapeutics, Inc. has a twelve month low of $6.43 and a twelve month high of $29.74. The company’s 50 day moving average is $14.02 and its two-hundred day moving average is $11.90. The stock has a market cap of $546.41 million, a P/E ratio of -5.99 and a beta of 0.62.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.12. On average, equities research analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Insider Activity at Rapport Therapeutics

In other news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $15.00, for a total transaction of $127,500.00. Following the sale, the insider owned 426,642 shares in the company, valued at approximately $6,399,630. The trade was a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 25,500 shares of company stock worth $365,500 in the last 90 days. 13.57% of the stock is currently owned by insiders.

Analysts Set New Price Targets

RAPP has been the topic of a number of research reports. HC Wainwright started coverage on Rapport Therapeutics in a research note on Wednesday, August 6th. They set a “buy” rating and a $31.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and set a $28.00 target price on shares of Rapport Therapeutics in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Rapport Therapeutics presently has a consensus rating of “Buy” and an average target price of $29.50.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.